​

Glaukos (GKOS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

GKOS Stock Forecast

Glaukos (GKOS) stock forecast, based on 22 Wall Street analysts, predicts a 12-month average price target of $154.00, with a high of $185.00 and a low of $120.00. This represents a 70.62% increase from the last price of $90.26.

$50 $80 $110 $140 $170 $200 High: $185 Avg: $154 Low: $120 Last Closed Price: $90.26

GKOS Stock Rating

Glaukos stock's rating consensus is Buy, based on 22 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 17 Buy (77.27%), 4 Hold (18.18%), 1 Sell (4.55%), and 0 Strong Sell (0.00%).

Buy
Total 22 0 1 4 17 Strong Sell Sell Hold Buy Strong Buy

GKOS Price Target Upside V Benchmarks

TypeNameUpside
StockGlaukos70.62%
SectorHealthcare Stocks 35.94%
IndustryMedical Device Stocks21.01%

Price Target Trends

1M3M12M
# Anlaysts--17
Avg Price Target--$139.76
Last Closing Price$90.26$90.26$90.26
Upside/Downside--54.84%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 2531011-15
Mar, 2531011-15
Feb, 253821-14
Jan, 253821-14
Dec, 243841-16
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 31, 2024Thomas StephanStifel Nicolaus$175.00$149.9416.71%93.88%
Dec 18, 2024Richard NewitterTruist Financial$185.00$145.1427.46%104.96%
Dec 02, 2024Thomas StephanStifel Nicolaus$153.00$140.189.15%69.51%
Dec 02, 2024Patrick WoodMorgan Stanley$120.00$140.80-14.77%32.95%
Nov 05, 2024David SaxonNeedham$149.00$127.4516.91%65.08%
Nov 05, 2024Ryan ZimmermanBTIG$140.00$127.869.49%55.11%
Oct 29, 2024Michael SarconeJefferies$155.00$134.0815.60%71.73%
Oct 21, 2024Samuel BrodovskyTruist Financial$152.00$132.8714.40%68.40%
Oct 17, 2024Matt O'BrienPiper Sandler$140.00$128.209.20%55.11%
Sep 23, 2024Ryan ZimmermanBTIG$139.00$127.788.78%54.00%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 03, 2025BTIGBuyBuyhold
Dec 11, 2024CitigroupBuyBuyupgrade
Dec 02, 2024Morgan StanleyEqual-WeightUnderweightdowngrade
Oct 29, 2024JefferiesBuyBuyhold
Oct 17, 2024Piper SandlerOverweightOverweighthold
Sep 23, 2024BTIGBuyBuyhold
Aug 28, 2024BTIGBuyBuyhold
Jul 15, 2024Morgan StanleyEqual-WeightEqual-Weighthold
May 22, 2024Wells FargoBuyBuyhold
May 22, 2024CitigroupBuyBuyhold

Financial Forecast

EPS Forecast

$-3 $-2 $-1 $0 $1 $2 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.70$-1.07$-2.09$-2.78$-2.77----
Avg Forecast$-1.50$-0.88$-2.20$-2.22$-1.82$-1.05$-0.25$0.42$1.18
High Forecast$-1.40$-0.82$-2.02$-2.16$-1.71$-0.75$0.08$0.44$1.24
Low Forecast$-1.58$-0.92$-2.30$-2.26$-2.00$-1.32$-0.38$0.39$1.12
Surprise %80.00%21.59%-5.00%25.23%52.20%----

Revenue Forecast

$200M $360M $520M $680M $840M $1B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$224.96M$294.01M$282.86M$314.71M$383.48M----
Avg Forecast$220.00M$288.16M$279.63M$313.00M$378.54M$479.13M$609.94M$745.10M$916.05M
High Forecast$228.57M$299.38M$289.59M$313.16M$378.96M$499.83M$610.76M$776.53M$954.70M
Low Forecast$208.57M$273.19M$261.89M$312.87M$377.81M$458.02M$609.12M$713.86M$877.64M
Surprise %2.25%2.03%1.16%0.55%1.31%----

Net Income Forecast

$-200M $-140M $-80M $-20M $40M $100M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-120.35M$-49.59M$-99.19M$-134.66M$-146.37M----
Avg Forecast$-139.09M$-60.89M$-56.35M$-134.66M$-89.64M$-50.13M$-7.30M$20.10M$57.15M
High Forecast$-111.27M$-45.79M$-39.19M$-95.11M$-82.63M$-36.24M$4.00M$21.20M$60.29M
Low Forecast$-166.91M$-75.99M$-73.50M$-174.21M$-96.64M$-64.01M$-18.60M$19.00M$54.04M
Surprise %-13.47%-18.55%76.04%-63.29%----

GKOS Forecast FAQ

Is Glaukos stock a buy?

Glaukos stock has a consensus rating of Buy, based on 22 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 17 Buy, 4 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Glaukos is a favorable investment for most analysts.

What is Glaukos's price target?

Glaukos's price target, set by 22 Wall Street analysts, averages $154 over the next 12 months. The price target range spans from $120 at the low end to $185 at the high end, suggesting a potential 70.62% change from the previous closing price of $90.26.

How does Glaukos stock forecast compare to its benchmarks?

Glaukos's stock forecast shows a 70.62% upside, outperforming the average forecast for the healthcare stocks sector (35.94%) and outperforming the medical device stocks industry (21.01%).

What is the breakdown of analyst ratings for Glaukos over the past three months?

  • April 2025: 20.00% Strong Buy, 66.67% Buy, 6.67% Hold, 6.67% Sell, 0% Strong Sell.
  • March 2025: 20.00% Strong Buy, 66.67% Buy, 6.67% Hold, 6.67% Sell, 0% Strong Sell.
  • February 2025: 21.43% Strong Buy, 57.14% Buy, 14.29% Hold, 7.14% Sell, 0% Strong Sell.

What is Glaukos’s EPS forecast?

Glaukos's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.05, marking a -62.09% decrease from the reported $-2.77 in 2024. Estimates for the following years are $-0.25 in 2026, $0.42 in 2027, and $1.18 in 2028.

What is Glaukos’s revenue forecast?

Glaukos's average annual revenue forecast for its fiscal year ending in December 2025 is $479.13M, reflecting a 24.94% increase from the reported $383.48M in 2024. The forecast for 2026 is $609.94M, followed by $745.1M for 2027, and $916.05M for 2028.

What is Glaukos’s net income forecast?

Glaukos's net income forecast for the fiscal year ending in December 2025 stands at $-50.125M, representing a -65.75% decrease from the reported $-146M in 2024. Projections indicate $-7.3M in 2026, $20.1M in 2027, and $57.15M in 2028.